Several case reports have also demonstrated decreased progression and improved prognosis of LMD from breast cancer following intrathecal trastuzumab, a monoclonal antibody that targets malignant cells that overexpress HER2 [63–66]. Here, ERBB2 is linked to breast carcinoma.